Global Alpha 1 Antitrypsin Deficiency Treatment Supply, Demand and Key Producers, 2026-2032

The global Alpha 1 Antitrypsin Deficiency Treatment market size is expected to reach $ 4400 million by 2032, rising at a market growth of 8.8% CAGR during the forecast period (2026-2032).

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

This report studies the global Alpha 1 Antitrypsin Deficiency Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Alpha 1 Antitrypsin Deficiency Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Alpha 1 Antitrypsin Deficiency Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Alpha 1 Antitrypsin Deficiency Treatment total market, 2021-2032, (USD Million)

Global Alpha 1 Antitrypsin Deficiency Treatment total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Alpha 1 Antitrypsin Deficiency Treatment total market, key domestic companies, and share, (USD Million)

Global Alpha 1 Antitrypsin Deficiency Treatment revenue by player, revenue and market share 2021-2026, (USD Million)

Global Alpha 1 Antitrypsin Deficiency Treatment total market by Indication, CAGR, 2021-2032, (USD Million)

Global Alpha 1 Antitrypsin Deficiency Treatment total market by End Users, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Alpha 1 Antitrypsin Deficiency Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Alpha 1 Antitrypsin Deficiency Treatment market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Indication, and by End Users. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Alpha 1 Antitrypsin Deficiency Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Alpha 1 Antitrypsin Deficiency Treatment Market, Segmentation by Indication:
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other

Global Alpha 1 Antitrypsin Deficiency Treatment Market, Segmentation by End Users:
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes

Companies Profiled:
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences

Key Questions Answered

1. How big is the global Alpha 1 Antitrypsin Deficiency Treatment market?

2. What is the demand of the global Alpha 1 Antitrypsin Deficiency Treatment market?

3. What is the year over year growth of the global Alpha 1 Antitrypsin Deficiency Treatment market?

4. What is the total value of the global Alpha 1 Antitrypsin Deficiency Treatment market?

5. Who are the Major Players in the global Alpha 1 Antitrypsin Deficiency Treatment market?

6. What are the growth factors driving the market demand? Show more